Vis enkel innførsel

dc.contributor.authorden Exter, Paul L.
dc.contributor.authorWoller, Scott C.
dc.contributor.authorRobert-Ebadi, Helia
dc.contributor.authorMasias, Camila
dc.contributor.authorMorange, Pierre-Emmanuel
dc.contributor.authorCastelli, David
dc.contributor.authorHansen, John Bjarne
dc.contributor.authorGeersing, Geert-Jan
dc.contributor.authorSiegal, Deborah M.
dc.contributor.authorde Wit, Kerstin
dc.contributor.authorKlok, Frederikus A.
dc.date.accessioned2023-02-14T07:15:21Z
dc.date.available2023-02-14T07:15:21Z
dc.date.issued2022-07-20
dc.description.abstractPatients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent recurrent VTE and death, which exposes them to an inherent increased risk of bleeding. Identification of patients at high risk of bleeding, and mitigating this risk, is an essential component of the immediate and long-term therapeutic management of VTE. The bleeding risk can be estimated by either implicit judgment, weighing individual predictors (clinical variables or biomarkers), or by risk prediction tools developed for this purpose. Management of bleeding risk in clinical practice is, however, far from standardized. International guidelines are contradictory and lack clear and consistent guidance on the optimal management of bleeding risk. This report of the ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease summarizes the evidence on the prediction of bleeding in VTE patients. We systematically searched the literature and identified 34 original studies evaluating either predictors or risk prediction models for prediction of bleeding risk on anticoagulation in VTE patients. Based on this evidence, we provide recommendations for the standardized management of bleeding risk in VTE patients.en_US
dc.identifier.citationden Exter, Woller, Robert-Ebadi, Masias, Morange, Castelli, Hansen, Geersing, Siegal, de Wit, Klok. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Journal of Thrombosis and Haemostasis. 2022;20(8):1910-1919en_US
dc.identifier.cristinIDFRIDAID 2053475
dc.identifier.doi10.1111/jth.15776
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/10037/28543
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalJournal of Thrombosis and Haemostasis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleManagement of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Diseaseen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)